anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Furfural is produced in one step at both high yield and high conversion from a feedstock comprising solid biomass and/or insoluble polysaccharide, in a high boiling, water-miscible solvent containing a soluble acid catalyst, and water. Furfural product and water can be distilled off, leaving non-volatile solvent behind. Because furfural contact with the acidic medium is minimized, degradation is kept to a minimum. The feedstock does not have to be pretreated. Because the biomass undergoes near complete dissolution, the residual material is flowable and easier to handle than residual solids reported from other processes. Further, certain by-products (e.g., humins, lignins) solubilized in the reaction solvent can be precipitated by addition of water or aqueous solution and then removed from the reaction mixture.
Pain experiences are often complex with catastrophic cognitions, emotions, and behaviors. Cognitive behavioral therapists share the work of unraveling these complex experiences with their patients. However, the change process underlying the unraveling of the pain experience have not yet been quantified. We used an interrelationship-focused network model to examine the way an undifferentiated conceptualization between cognition and pain experience changed via group cognitive-behavioral therapy (CBT). Overall, 65 participants (77.4% of all patients who entered the intervention) were included in the analysis; they attended the total of 12 weekly group CBT and filled the Short-Form McGill Pain Questionnaire and the pain catastrophizing questionnaire. Before treatment, there were no edges in the partial correlation-based network because of large covariation across items. After treatment, many edges appeared and, particularly strong couplings were found between items within the same subscale. The formative shift from a non-edged pre-treatment network to a mature post-treatment network may indicate that patients were able to conceptualize these symbolic constructs better. These results are probably of interest to clinicians and would be consistent with the fundamental monitoring process of CBT.
The ventilator modality of automatic tube compensation (ATC) can provide variable pressure supports during the weaning process to overcome any change in the resistance of the breathing circuit, endotracheal tube, and airways. ATC is effective in overcoming the work of breathing caused by airway resistance to allow successful weaning process and extubation. Pressure support ventilation (PSV) has been widely used in the performance of a spontaneous breathing trial because it can compensate to some extent for the additional work of breathing imposed by the endotracheal tube and the breathing circuit. However, it is difficult to recognise the exact pressure support to overcome the tubing resistance during the weaning process till extubation. The aim of the study is to evaluate the automatic tube compensation (ATC) as a tool for ventilatory weaning in pediatrics after surgeries for congenital cardiac anomalies. The primary objective of our study is to compare the efficacy of ATC versus PS as a modality for ventilatory weaning of pediatric postcardiac surgery as regards effects on work of breathing, lung compliance, and alveolar recruitment. The secondary objective is to determine perioperative predictors of extubation failure (requirement for reintubation and mechanical ventilation after prior successful weaning from ventilation, within 48 hours after extubation) after cardiac surgery. Patients will be included after fulfilling weaning criteria and being pain free. a weaning trial for 30 minutes will be commenced according to the following and assessed by the attending physician:- Group A: Weaning trial will be done for 17 patients using PSV 0 cmH2O with 100% automatic tube compensation (ATC).

Group P: Weaning trial will be done for 17 patients using PSV 8 cmH2O without ATC.
PROBLEM TO BE SOLVED: To obtain a dibenzofuran derivative useful as an ultraviolet light absorber, antioxidant, anthelminthic, etc., by culturing lichenic germs isolated from lichens. SOLUTION: This dibenzofuran derivative, which is a compound of the formula or its salt, and can be effectively used as a medicinal or agrochemical agent, such as anthelmithic, sunscreen and food additive, is obtained by culturing lichenic germs separated from Stereocaulon japonicum Th. Fr. or its analog, and recovering the product from the culture liquid. The separation of the lichenic germs from Stereocaulon japonicum Th. Fr. comprises, for example, collecting Stereocaulon japonicum Th.  Fr., air-drying the lichen, cutting off and collecting parts of cysts, immersing them in distilled water for 30min, attaching the wet cysts to a lid of a Petri dish in which agar is layered, allowing g the Petri dish to stand at room temperature for approximately two days, so that spores are released onto the agar surface, separating the spore, thus obtaining lichenic germs, and culturing the lichenic germs in a culture medium, such as ordinary medium which contains a malt extract or yeast extract, as the main component, at 15-20 deg.C for 50-200 days.
After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
Oxymorphone Hydrochloride Tablets are a semi-synthetic opioid analgesic supplied in 5 mg and 10 mg tablet strengths for oral administration. The tablet strengths describe the amount of oxymorphone hydrochloride per tablet. The tablets contain the following inactive ingredients: magnesium stearate, microcrystalline cellulose, and pregelatinized starch.

Chemically, oxymorphone hydrochloride is 4, 5α-epoxy-3, 14-dihydroxy-17-methylmorphinan-6-one hydrochloride, a white or slightly off-white, odorless powder, which is sparingly soluble in alcohol and ether, but freely soluble in water. The molecular weight of oxymorphone hydrochloride is 337.80. The pKa1 and pKa2 of oxymorphone at 37°C are 8.17 and 9.54, respectively. The octanol/aqueous partition coefficient at 37°C and pH 7.4 is 0.98.

The structural formula for oxymorphone hydrochloride is as follows:
PURPOSE:To provide a dental prothesis having a color tone for developing the opal effect similar to the enamel of a natural tooth. CONSTITUTION:The material mixture consisting of Li2CO3, Na2SiF6, SiO2, Al2O3, MgO, ZrO2, and ZnO as main constituents, TiO2 as coloring oxide, and other coloring oxides is heated up to 750 deg.C at a speed of 13 deg.C/min., and kept for two hours at the temperature. The temperature rise speed is reduced, and heat treatment is applied in the max. temperature range of 780-890 deg.C, and the castable ceramic material having the dimension of a crystal phase of 0.01-0.30mum is obtained. This material shows a brown color like opal and contains lithium aluminium silicate group crystals. A dental prothesis is made by using the crystal ceramic material according to the ordinary method.
A terpenoid assembled organic single-molecule photothermal reagent with triple response of chemotherapy, photo-thermal and photodynamic, and its preparation and application are provided. The invention belongs to the field of biological medicine materials and preparation thereof. The invention aims to solve the technical problems that the existing photosensitizer cannot synchronously realize triple effects of chemotherapy, photo-thermal and photodynamic and cannot achieve both high PTT activity and PDT activity. The photothermal reagent is formed by covalent coupling of terpenoid Natural Small Molecules (NSMs) and chlorin e6 (Ce 6) through a coupling agent containing disulfide bonds. Through covalent coupling of disulfide bonds with NSMs and Ce6 molecules, different connecting arms are selected according to the terpene micromolecule active sites, so that a single-molecule photothermal reagent precursor NSMs-SS-Ce6 is constructed, and finally, the nano system of the photothermal reagent precursor has high-efficiency PTT activity, chemotherapy and PDT activity. The terpenoid assembled organic single-molecule photo-thermal reagent is used for preparing anti-tumor drugs.
Patients with chronic myeloid leukemia (CML) who have failed conventional tyrosine kinase inhibitors (cTKIs) and asciminib constitute a complex group of patients with few therapeutic options. A retrospective descriptive multicenter observational study was carried out including patients with CML who had presented a therapeutic failure to ≥ 2 cTKIs and asciminib, and had received or were not candidates to ponatinib. Of the 19 patients enrolled, 8 patients failed asciminib due to intolerance and 11 due to resistance. The most common strategy for intolerant patients was to initiate a previously administered cTKI (6/8) with dose adjustments or symptomatic management of adverse events (AEs). Of the patients who failed due to resistance, only patients who underwent progenitor transplantation achieved profound long-term responses. A frequent strategy was to use ponatinib (4/11) in patients previously considered non-candidates, with poor responses in patients in whom dose reductions were used, and severe AEs in patients at standard doses. In the remaining patients, cTKIs and other agents (interferon, hydroxyurea, citarabine, busulfan) were used with poor responses. Patients who progressed to advanced stages had a dismal prognosis. With a median follow-up of 11.2 months, overall survival of the global cohort was 73%; 100% for intolerant patients, 71% for resistant patients and 25% for those who discontinue asciminib in accelerated/blastic phase.
A capsule composition containing a capsule and a stabilizing agent. The capsule has an oil core containing an active material and a capsule wall encapsulating the oil core. The active material is a fragrance, a flavor, a malodor counteractant, or a combination thereof. The wall is formed of polyurea or polyurethane. The capsule composition has 20 ppm or greater of the stabilizing agent, which is a multi-functional amine, an amino acid, a polymer mixture, or a combination thereof. Also disclosed is a consumer product containing this capsule composition.
In control group patients, if any pollution occurs in the wound area (feces, discharge) in the sterile dressing performed in the morning and evening at 10-22 hours, the wound area will be cleaned with the help of 0.9% isotonic sodium chloride washing solution and the clinical routine application of the pressure injury of the hospital will be carried out according to the physician's order. In patients in the control group, the results of the application will be recorded and wound healing status will be observed. An in-bed position will be given every 2 hours for the prevention and care of pressure injury patients of the control group patients. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure and other), the necessary treatment and care will be performed.
Physically accurate (authentic) reproduction of affective touch patterns on the forearm is limited by actuator technology. However, in most VR applications a direct comparison with actual touch is not possible. Here, the plausibility is only compared to the user's expectation. Focusing on the approach of plausible instead of authentic touch reproduction enables new rendering techniques, like the utilization of the phantom illusion to create the sensation of moving vibrations. Following this idea, a haptic armband array (4x2 vibrational actuators) was built to investigate the possibilities of recreating plausible affective touch patterns with vibration. The novel aspect of this work is the approach of touch reproduction with a parameterized rendering strategy, enabling the integration in VR. A first user study evaluates suitable parameter ranges for vibrational touch rendering. Duration of vibration and signal shape influence plausibility the most. A second user study found high plausibility ratings in a multimodal scenario and confirmed the expressiveness of the system. Rendering device and strategy are suitable for a various stroking patterns and applicable for emerging research on social affective touch reproduction.
Risk Summary

There are no available data on the effects of TUDORZA PRESSAIR or aclidinium bromide on the breastfed child or on milk production or presence in human milk. Aclidinium bromide is present in milk of lactating female rats [see Data]. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TUDORZA PRESSAIR and any potential adverse effects on the breastfed child from TUDORZA PRESSAIR or from the underlying maternal condition.

Data

In a pharmacokinetic study, levels of radioactivity in milk and plasma in rats were measured after a single intravenous dose of 1 mg/kg of radiolabeled aclidinium bromide on approximately post-natal day 14 [see Use in Specific Populations (8.1)]. The maximum concentration of radioactivity [14C-aclidinium] in milk was measured at 6 hours post-dose and was found to be 10-14 times higher than in plasma.
BACKGROUND: Existing animal models for testing therapeutics in the skin are limited. Mouse and rat models lack similarity to human skin in structure and wound healing mechanism. Pigs are regarded as the best model with regards to similarity to human skin; however, these studies are expensive, time-consuming, and only small numbers of biologic replicates can be obtained. In addition, local-regional effects of treating wounds that are closely adjacent to one-another with different treatments make assessment of treatment effectiveness difficult in pig models. Therefore, here, a novel nude mouse model of xenografted porcine hypertrophic scar (HTS) cells was developed. This model system was developed to test if supplying hypo-pigmented cells with exogenous alpha melanocyte stimulating hormone (α-MSH) will reverse pigment loss in vivo.
METHODS: Dyschromic HTSs were created in red Duroc pigs. Epidermal scar cells (keratinocytes and melanocytes) were derived from regions of hyper-, hypo-, or normally pigmented scar or skin and were cryopreserved. Dermal fibroblasts (DFs) were isolated separately. Excisional wounds were created on nude mice and a grafting dome was placed. DFs were seeded on day 0 and formed a dermis. On day 3, epidermal cells were seeded onto the dermis. The grafting dome was removed on day 7 and hypo-pigmented xenografts were treated with synthetic α-MSH delivered with microneedling. On day 10, the xenografts were excised and saved. Sections were stained using hematoxylin and eosin hematoxylin and eosin (H&E) to assess xenograft structure. RNA was isolated and quantitative real-time polymerase chain reaction (qRT-PCR) was performed for melanogenesis-related genes TYR, TYRP1, and DCT.
RESULTS: The seeding of HTSDFs formed a dermis that is similar in structure and cellularity to HTS dermis from the porcine model. When hyper-, hypo-, and normally-pigmented epidermal cells were seeded, a fully stratified epithelium was formed by day 14. H&E staining and measurement of the epidermis showed the average thickness to be 0.11 ± 0.07 µm vs. 0.06 ± 0.03 µm in normal pig skin. Hypo-pigmented xenografts that were treated with synthetic α-MSH showed increases in pigmentation and had increased gene expression of TYR, TYRP1, and DCT compared to untreated controls (TYR: 2.7 ± 1.1 vs. 0.3 ± 1.1; TYRP1: 2.6 ± 0.6 vs. 0.3 ± 0.7; DCT 0.7 ± 0.9 vs. 0.3 ± 1-fold change from control; n = 3).
CONCLUSIONS: The developed nude mouse skin xenograft model can be used to study treatments for the skin. The cells that can be xenografted can be derived from patient samples or from pig samples and form a robust dual-skin layer containing epidermis and dermis that is responsive to treatment. Specifically, we found that hypo-pigmented regions of scar can be stimulated to make melanin by synthetic α-MSH in vivo.
The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective. Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism.

Thyroid hormones should be used with great caution in a number of circumstances where the integrity of the cardiovascular system, particularly the coronary arteries, is suspected. These include patients with angina pectoris or the elderly, in whom there is a greater likelihood of occult cardiac disease. In these patients, liothyronine sodium therapy should be initiated with low doses, with due consideration for its relatively rapid onset of action. Starting dosage of liothyronine sodium tablets is 5 mcg daily, and should be increased by no more than 5 mcg increments at 2-week intervals. When, in such patients, a euthyroid state can only be reached at the expense of an aggravation of the cardiovascular disease, thyroid hormone dosage should be reduced.

Morphologic hypogonadism and nephrosis should be ruled out before the drug is administered. If hypopituitarism is present, the adrenal deficiency must be corrected prior to starting the drug.

Myxedematous patients are very sensitive to thyroid; dosage should be started at a very low level and increased gradually.

Severe and prolonged hypothyroidism can lead to a decreased level of adrenocortical activity commensurate with the lowered metabolic state. When thyroid-replacement therapy is administered, the metabolism increases at a greater rate than adrenocortical activity. This can precipitate adrenocortical insufficiency. Therefore, in severe and prolonged hypothyroidism, supplemental adrenocortical steroids may be necessary. In rare instances the administration of thyroid hormone may precipitate a hyperthyroid state or may aggravate existing hyperthyroidism.
The present invention relates to a capsule capable of replenishing the brain, tonifying the kidney and moistening the intestine, which belongs to the technical field of a traditional Chinese medicine. The problem to be solved by the present invention is to provide a new medicine for treating the diseases of the brain, the kidney and the intestine. The scheme for solving the problem has the key point that the capsule is prepared from the traditional Chinese medicines of antelope horn powder, seed of ferther cockscomb, etc. The capsule has the effects of supplementing brain marrow, making up congenital or acquired defects, loosening bowel to relieve constipation, benefiting vital energy, clearing the liver and improving eyesight. The capsule is indicated on new and old constipation, constrained stomach and intestine, dim eyesight (with repeatedly moving objects in the sight) and faint. In addition, the capsule has an outstanding effect in the aspects of headache, kidney invigorating, tendon and bone strengthening, apoplexy, spasm, etc. The capsule has the advantages of no toxic or side effect, suitability for both the young and the old and quick effect in 3 to 5 days.
The invention provides a conjugate comprising FGF or other polypeptide reactive with an FGF receptor, and a cytotoxic agent. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, although other cytotoxic agents can also be advantageously used. The cytotoxic agent can be attached to FGF through a chemical bond or the composition can be prepared as a chimera, using techniques of recombinant DNA. The conjugate can be used to treat FGF-mediated pathophysiological conditions by specifically targeting cells having FGF receptors and inhibiting proliferation of or causing death of the cells. Additionally, the conjugate can be used to target cytotoxic agents into cells having FGF receptors, and to inhibit the proliferation of such cells. A method of purifying the conjugate on an immobilized heparin column is also provided.
In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
<P>PROBLEM TO BE SOLVED: To obtain a new pharmaceutical composition as a new antitumor agent, and to provide a new health food product, i.e. health tea.  <P>SOLUTION: The pharmaceutical composition contains a Taxus yunnanensis plant or a processed product thereof and a Tecoma ipe Mart. ex K. Shum. plant or a processed product thereof. The food composition contains the Taxus yunnanensis plant or the processed product thereof and the Tecoma ipe Mart. ex K. Shum. plant or the processed product thereof. The health tea as a health food product comprises a blend of the xylum of the Taxus yunnanensis plant finely chopped to 30-mesh-passable particles with the bast of the Tecoma ipe Mart. ex K. Shum. plant finely chopped to 30-mesh-passable particles.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE: A mask sheet and a manufacturing method thereof are provided to improve a skin care effect by maximizing the transfer capability of active ingredients. CONSTITUTION: A manufacturing method of mask sheet is as follows. A composition for manufacturing a sheet is prepared by mixing tapioca starch, vegetable starch, carrageenan, and mannan in a predetermined ratio(S200). The composition for manufacturing a sheet and purified water are mixed in the ratio of 1:4 at the room temperature(S210). The mixture is gelatinized by being heated at 75-85 deg.C for 30-40 minutes(S220). The gelatinized product is formed in a sheet form by being poured into a mold(S230). A vegetable starch sheet is completed by drying the product in a dryer(S240). [Reference numerals] (AA) Preparing composition for manufacturing a sheet using tapioca starch, vegetable starch, carrageenan, and mannan(step200); (BB) Mixing composition for manufacturing a sheet and purified water(step210); (CC) Gelatinization of the mixture by heating the mixture(step220); (DD) Forming in a sheet form by pouring gelatinized product into a mold(step230); (EE) Completing vegetable starch sheet by drying product in a dryer(step240)
Enrichment of S and Z polymorphisms of alpha-1-antitrypsin (AAT) in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chemical/biological/immunological events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metabolism. AAT, its regulation, and iron metabolism represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression.